Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19

Cited by (1,000)

Items 201–300 of 1,000

1. Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
   James Jiqi Wang, Matthew L. Edin, Darryl C. Zeldin, Chenze Li, Dao Wen Wang, Chen Chen · 2020 · Pharmacology & Therapeutics
2. Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study
   Zhichao Feng, Jennifer S.Y. Li, Shanhu Yao, Qizhi Yu, Wenming Zhou, Xiaowen Mao, Huiling Li, Wendi Kang, Xin Ouyang, Mei Ji et al. · 2020 · Aging and Disease
3. Glucocorticoid excess and COVID-19 disease
   Valentina Guarnotta, Rosario Ferrigno, Marianna Martino, Mattia Barbot, Andrea Maria Isidori, Carla Maria Scaroni, Angelo Ferrante, Giorgio Arnaldi, Rosario Pivonello, Carla Santos de Souza Giordano · 2020 · Reviews in Endocrine and Metabolic Disorders
4. COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management
   Md. Farhad Hossain, Sharifa Hasana, Abdullah Al Mamun, Md. Sahab Uddin, Mir Imam Ibne Wahed, Sabarni Sarker, Tapan Behl, Irfan Ullah, Yesmin Begum, Israt Jahan Bulbul et al. · 2020 · Frontiers in Pharmacology
5. Risk factors for myocardial injury and death in patients with COVID-19: insights from a cohort study with chest computed tomography
   Giuseppe Ferrante, Fabio Fazzari, Ottavia Cozzi, Matteo Maurina, Renato Bragato, Federico D’Orazio, Chiara Torrisi, Ezio Lanza, Eleonora Indolfi, Valeria Donghi et al. · 2020 · Cardiovascular Research
6. Issues for the management of people with diabetes and COVID-19 in ICU
   Antonio Ceriello, Eberhard Standl, Doina Catrinoiu, Baruch Itzhak, Nebojsa M. Lalic, Dario Rahelić, Oliver Schnell, Jan Škrha, Paul Elie Valensi · 2020 · Cardiovascular Diabetology
7. Drug Design Strategies for the Treatment of Viral Disease. Plant Phenolic Compounds and Their Derivatives
   Monika Kowalczyk, Aleksandra Golonko, Renata Świsłocka, Monika Kalinowska, Monika Parcheta, Artur Hugo Swiergiel, W. Lewandowski · 2021 · Frontiers in Pharmacology
8. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients
   Gianluca Trifirò, Marco Massari, Roberto Da Cas, Francesca Menniti‐Ippolito, Janet Sultana, Salvatore Crisafulli, Paolo Giorgi Rossi, Massimiliano Marino, Manuel Zorzi, Emanuela Bovo et al. · 2020 · Drug Safety
9. Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
   Rangaprasad Sarangarajan, Robert A. Winn, Michael A. Kiebish, C. Bountra, Elder Granger, Niven R. Narain · 2020 · Journal of Racial and Ethnic Health Disparities
10. Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin–angiotensin-aldosterone system (RAAS) dysregulation
    Robin Augustine, Abhilash S, Ajisha Nayeem, Shaheen Abdul Salam, Priya Augustine, Pan Dan, Pablo Maureira, Fatima Mraiche, Carmine Gentile, Philip M. Hansbro et al. · 2021 · Chemico-Biological Interactions
11. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
    The Task Force for the management of COVID-19 of the European Society of Cardiology, Colin Baigent, Stephan Windecker, Daniele Andreini, Elena Arbelo, Emanuele Barbato, Antonio Luca Bartorelli, Andreas Baumbach, Elijah Raphael Behr, Sérgio Luis Berti et al. · 2021 · Cardiovascular Research
12. Elevated Blood Pressure Increases Pneumonia Risk: Epidemiological Association and Mendelian Randomization in the UK Biobank
    Seyedeh Maryam Zekavat, Michael C. Honigberg, James P. Pirruccello, Puja Kohli, Elizabeth W. Karlson, Christopher Newton‐Cheh, Hongyu Zhao, Pradeep Natarajan · 2020 · Med
13. The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression Levels in Patients with Comorbidities on COVID-19 Severity: A Comprehensive Review
    Rui Rodrigues, Sofia Costa‐de‐Oliveira · 2021 · Microorganisms
14. Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
    Bryan Williams, Yi Zhang · 2020 · The Lancet
15. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study
    Matsuzawa, Yasushi, Ogawa, Hisao, Kimura, Kazuo, Konishi, Masaaki, Kirigaya, Jin, Fukui, Kazuki, Tsukahara, Kengo, Shimizu, Hiroyuki, Iwabuchi, Keisuke, Yamada, Yu et al. · 2020 · Hypertension Research
16. Edible mushrooms as potential functional foods in amelioration of hypertension
    Abdur Rauf, Payal B. Joshi, Zubair Ahmad, Hassan A. Hemeg, Ahmed Olatunde, Saima Naz, Nabia Hafeez, Jesús Simal‐Gándara · 2023 · Phytotherapy Research
17. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin–angiotensin system
    Annette K. Offringa, Roy C. Montijn, Sandeep Singh, M. Paul, Yigal M. Pinto, Sara‐Joan Pinto‐Sietsma · 2020 · European Heart Journal - Cardiovascular Pharmacotherapy
18. SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism
    Nitin Kumar, Yu Zuo, Srilakshmi Yalavarthi, Kristina L. Hunker, Jason S. Knight, Yogendra M. Kanthi, T. Andrea, Santhi K. Ganesh · 2020 · Viruses
19. Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities
    Weifang Liu, Chengzhang Yang, Yuangao Liao, Feng Wan, Lijin Lin, Xuewei Huang, Binghong Zhang, Yufeng Yuan, Peng Zhang, Xiao‐Jing Zhang et al. · 2021 · Journal of Infection and Public Health
20. Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System
    Timothy S. Chang, Yi Ding, Malika Kumar Freund, Ruth Johnson, Tommer Schwarz, Julie M. Yabu, Chad J. Hazlett, Jeffrey N. Chiang, Ami Wulf, UCLA Health Data Mart Working Group et al. · 2020 · medRxiv
21. SARS-CoV-2 (COVID-19) and the Endocrine System
    Michelle Diane Lundholm, Caroline A Poku, Nicholas Emanuele, Mary Ann Emanuele, Norma Lopez · 2020 · Journal of the Endocrine Society
22. Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis
    Anna E. Ssentongo, Paddy Ssentongo, Emily S. Heilbrunn, Alain Lekoubou, Ping Du, Duanping Liao, John S. Oh, Vernon M. Chinchilli · 2020 · Open Heart
23. Association between renin–angiotensin system inhibitors and COVID-19 complications
    Sophie Liabeuf, Julien Moragny, Youssef Bennis, Benjamin Batteux, Étienne Brochot, Jean‐Luc Schmit, Jean‐Philippe Lanoix, Claire Andréjak, O. Ganry, Michel Slama et al. · 2020 · European Heart Journal - Cardiovascular Pharmacotherapy
24. Nanotheranostics against COVID-19: From multivalent to immune-targeted materials
    Parichehr Hassanzadeh · 2020 · Journal of Controlled Release
25. Gender, age and comorbidities as the main prognostic factors in patients with COVID-19 pneumonia.
    Jun Mi, Weimin Zhong, Chaoqun Huang, Wanwan Zhang, Li Tan, Lili Ding · 2020 · PubMed Central
26. Coronavirus and Cardiometabolic Syndrome
    Jeffrey Ian Mechanick, Robert S. Rosenson, Sean Pinney, DONNA M. MANCINI, Jagat Narula, Valentı́n Fuster · 2020 · Journal of the American College of Cardiology
27. COVID-19 and the cardiovascular system: an update
    Joshua Kuimeta Salabei, Zekarias T. Asnake, Zeeshan H. Ismail, Kipson Charles, Greg Stanger, Abdullah H. Abdullahi, Andrew T Abraham, Peters Okonoboh · 2022 · The American Journal of the Medical Sciences
28. COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome
    Jianhua Hu, Xiaoli Zhang, Xuan Zhang, Hong Zhao, Jiangshan Lian, Shaorui Hao, Hongyu Jia, Meifang Yang, Yingfeng Lu, Dairong Xiang et al. · 2020 · Journal of Infection
29. Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021
    Safaet Alam, Taslima Binte Kamal, Md. Moklesur Rahman Sarker, Jin‐Rong Zhou, S. M. Abdur Rahman, Isa Naina Mohamed · 2021 · Frontiers in Pharmacology
30. COVID‐19 and renin‐angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) ‐ Is there any scientific evidence for controversy?
    Aneta Aleksova, Federico Ferro, Giulia Gagno, Chiara Cappelletto, Daniela Santon, Maddalena Rossi, Giuseppe Ippolito, Alimuddin I. Zumla, Antonio Paolo Beltrami, Gianfranco Sinagra · 2020 · Journal of Internal Medicine
31. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety
    Saghir Akhtar, Ibrahim F. Benter, Mohammed Ibn-Mas’ud Danjuma, Suhail A.R. Doi, Syed Shahzad Hasan, Abdella M. Habib · 2020 · Journal of drug targeting
32. El suplemento con altas dosis de vitamina D podría representar una alternativa promisoria para prevenir o tratar la infección por COVID-19
    José Luis Mansur, Carlos Daniel Tajer, Javier A. Mariani, Felipe Inserra, León Ferder, Walter A. Manucha · 2020 · Clínica e Investigación en Arteriosclerosis
33. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients
    Loris Zamai · 2020 · Cells
34. Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19
    Abbas Soleimani, Sina Kazemian, Shahrokh Karbalai Saleh, Arya Aminorroaya, Zahra Shajari, Azar Hadadi, Mohammad Talebpour, Hakimeh Sadeghian, Pooya Payandemehr, Mehran Sotoodehnia et al. · 2020 · American Journal of Hypertension
35. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies
    Augusto Filippo Di Castelnuovo, Simona Costanzo, Andrea Antinori, Nausicaa Berselli, Lorenzo Blandi, Marialaura Bonaccio, Roberto Cauda, Alessandro Gialluisi, Giovanni Guaraldi, Lorenzo Menicanti et al. · 2020 · Vascular Pharmacology
36. Role of Hydrogen Bonds in Formation of Co-amorphous Valsartan/Nicotinamide Compositions of High Solubility and Durability with Anti-hypertension and Anti-COVID-19 Potential
    Marika Turek, Ewa Różycka‐Sokołowska, Marek Koprowski, Bernard Marciniak, Piotr Bałczewski · 2021 · Molecular Pharmaceutics
37. SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?
    Armando Rojas R, Ileana González, Miguel Angel Morales · 2020 · Inflammation Research
38. Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic?
    Luciano F. Drager, Andrea Pio-Abreu, Renato D. Lópes, Luiz Aparecido Bortolotto · 2020 · Current Hypertension Reports
39. The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis
    Jiuyang Xu, Yaqun Teng, Lianhan Shang, Xiaoying Gu, Guohui Fan, Yijun Chen, Ran Tian, Shuyang Zhang, Bin Cao · 2020 · Clinical Infectious Diseases
40. Stroke Care during the COVID-19 Pandemic: International Expert Panel Review
    Narayanaswamy Venketasubramanian, Craig S. Anderson, Hakan Ay, Selma Aybek, Waleed Brinjikji, Gabriel R. de Freitas, Óscar H. Del Brutto, Klaus C Fassbender, Miki Fujimura, Larry B. Goldstein et al. · 2021 · Cerebrovascular Diseases
41. Implications of COVID‐19 for an ageing population
    Nicolette R. Holt, Franz–Josef Neumann, John J. McNeil, Allen C Cheng · 2020 · The Medical Journal of Australia
42. Endocrine Conditions and COVID-19
    Skand Shekhar, Rachel Wurth, Crystal Dawn Chrysavgi Kamilaris, Graeme Eisenhofer, Francisco J. Barrera, Michelle Hajdenberg, Joselyne Tessa Tonleu, Janet Elizabeth Hall, Ernesto L. Schiffrin, Forbes D. Porter et al. · 2020 · Hormone and Metabolic Research
43. Pathogenesis and Management of Myocardial Injury in Coronavirus Disease 2019
    Zhiyao Wei, Yong‐Jian Geng, Ji Huang, Hai‐Yan Qian · 2020 · European Journal of Heart Failure
44. Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding
    Jordana B. Cohen, Lucy D’Agostino McGowan, Elizabeth T. Jensen, Joseph Rigdon, Andrew Michael South · 2020 · Journal of Hypertension
45. The Renin–Angiotensin–Aldosterone System and Coronavirus Disease 2019
    Eliécer Coto, Pablo Avanzas y, Juan Gómez · 2021 · European Cardiology Review
46. Do Changes in ACE-2 Expression Affect SARS-CoV-2 Virulence and Related Complications: A Closer Look into Membrane-Bound and Soluble Forms
    Huseyin Cagatay Yalcin, Vijayakumar Sukumaran, Mahmoud Khatib A. A. Al-Ruweidi, Samar Shurbaji · 2021 · International Journal of Molecular Sciences
47. Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review
    Annamaria Mascolo, Cristina Scavone, Concetta Rafaniello, Carmen Ferrajolo, Giorgio Racagni, Liberato Berrino, Giuseppe Paolisso, Francesco Rossi, Annalisa Capuano · 2020 · Frontiers in Cardiovascular Medicine
48. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor
    Murat Öz, Dietrich Ernst Lorke, Nadine Kabbani · 2020 · Pharmacology & Therapeutics
49. Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain
    Ángel Vila-Córcoles, Olga Ochoa Gondar, Eva María Satué-Gracia, Cristina Torrente‐Fraga, Fréderic Gómez-Bertomeu, Ángel Vila-Rovira, Cinta de Diego‐Cabanes, Ferran Bejarano‐Romero, Josep Basora · 2020 · BMJ Open
50. Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies
    Chirag Bavishi, Paul Kieran Whelton, Giuseppe Mancia, Giovanni Corrao, Franz H. Messerli · 2021 · Journal of Hypertension
51. Hospital bed occupancy rate is an independent risk factor for COVID-19 inpatient mortality: a pandemic epicentre cohort study
    Francesco Castagna, Xiaonan Xue, Omar Saeed, Rachna Kataria, Yoram A. Puius, Snehal R. Patel, Mario Jorge Garcia, Andrew D. Racine, Daniel B. Sims, Ulrich P. Jorde · 2022 · BMJ Open
52. Considerations for pharmacoepidemiological analyses in the SARS‐CoV ‐2 pandemic
    Anton Pottegård, Xavier Kurz, Nicholas D Moore, Christian Fynbo Christiansen, Olaf H. Klungel · 2020 · Pharmacoepidemiology and Drug Safety
53. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
    Gábor Kriszta, Zsófia Kriszta, Szilárd Váncsa, Péter Hegyi, Levente Frim, Bálint Mihály Erőss, Péter Hegyi, Gábor Pethö, Erika Pintér · 2021 · Frontiers in Pharmacology
54. Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2
    Harry F. Ridgway, Graham J. Moore, Thomas Mavromoustakos, Sotirios Tsiodras, Irene Ligielli, Konstantinos Kelaidonis, Christos T. Chasapis, Laura Kate Gadanec, Anthony Zulli, Vasso Apostolopoulos et al. · 2022 · Computational and Structural Biotechnology Journal
55. Renin–Angiotensin–Aldosterone System Inhibitors in Covid-19
    Greg Haug, Mathew S Eapen, Sukhwinder Singh Sohal · 2020 · New England Journal of Medicine
56. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
    Jiuyang Xu, Chaolin Huang, Guohui Fan, Zhibo Liu, Lianhan Shang, Fei Zhou, Yeming Wang, Jiapei Yu, Luning Yang, Ke Xie et al. · 2020 · Frontiers of Medicine
57. Cardiac Injury Patterns and Inpatient Outcomes Among Patients Admitted With COVID-19
    Mohamad Raad, Mohammed Ferras Dabbagh, Sarah Gorgis, Jerry Yan, Omar Chehab, Carina Dagher, Khaled Jamoor, Inaya Hajj Hussein, Bernard C Cook, Meredith Van Harn et al. · 2020 · The American Journal of Cardiology
58. Vitamin D high doses supplementation could represent a promising alternative to prevent or treat COVID-19 infection
    José Luis Mansur, Carlos Daniel Tajer, Javier A. Mariani, Felipe Inserra, León Ferder, Walter A. Manucha · 2020 · Clínica e Investigación en Arteriosclerosis (English Edition)
59. A Deep Learning Radiomics Model to Identify Poor Outcome in COVID-19 Patients With Underlying Health Conditions: A Multicenter Study
    Siwen Wang, Di Dong, Liang Li, Hailin Li, Yan Bai, Yahua Hu, Yuanyi Huang, Xiangrong Yu, Sibin Liu, Xiaoming Qiu et al. · 2021 · IEEE Journal of Biomedical and Health Informatics
60. Hypertension and Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
    Andrew Ip, Kaushal Parikh, Joseph E. Parrillo, Shivam Mathura, Eric Hansen, Ihor S. Sawczuk, Stuart L. Goldberg · 2020 · medRxiv
61. Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis
    Syed Shahzad Hasan, Chia Siang Kow, Muhammad Abdul Hadi, Syed Tabish Razi Zaidi, Hamid A. Merchant · 2020 · American Journal of Cardiovascular Drugs
62. Decreased in‐hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID‐19
    Mohammad Haji Aghajani, Omid Moradi, Hossein Amini, Hamed Azhdari Tehrani, Elham Pourheidar, Mohammad Mahdi Rabiei, Mohammad Sistanizad · 2021 · Journal of Medical Virology
63. The Association of Hypertension With the Severity of and Mortality From the COVID-19 in the Early Stage of the Epidemic in Wuhan, China: A Multicenter Retrospective Cohort Study
    Sumaira Mubarik, Xiaoxue Liu, Ehab S. Eshak, Keyang Liu, Qing Liu, Fang Wang, Fang Shi, Haoyu Wen, Jianjun Bai, Chuanhua Yu et al. · 2021 · Frontiers in Medicine
64. RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus
    Vasanth Kumar, Sanjay Agarwal, Banshi Saboo, Brij Mohan Makkar · 2022 · International Journal of Diabetes in Developing Countries
65. Deep-learning convolutional neural networks with transfer learning accurately classify COVID-19 lung infection on portable chest radiographs
    Shreeja Kikkisetti, Jocelyn Zhu, Beiyi Shen, Haifang Li, Timothy Q. Duong · 2020 · PeerJ
66. Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19
    Gustavo J.S. Pereira, Anderson H.F.F. Leão, Adolfo Garcia Erustes, Ingrid Beatriz de Melo Morais, Talita Aparecida de Moraes Vrechi, Lucas dos Santos Zamarioli, Cássia Arruda Souza Pereira, Laís de Oliveira Marchioro, Letícia Paulino Sperandio, Ísis Valeska Freire Lins et al. · 2021 · International Journal of Molecular Sciences
67. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19
    Masato Furuhashi, Norihito Moniwa, Hideki Takizawa, Nobuyuki Ura, Kazuaki Shimamoto · 2020 · Hypertension Research
68. Exercise as medicine for COVID-19: An ACE in the hole?
    Kevin S. Heffernan, Sae Young Jae · 2020 · Medical Hypotheses
69. COVID-19 and Advanced Practice Registered Nurses: Frontline Update
    Ana Dı́ez-Sampedro, Arturo González, Victoria Delgado, Monica Flowers, Tatayana Maltseva, Maria Olenick · 2020 · The Journal for Nurse Practitioners
70. Angiotensin II receptors: Impact for COVID ‐19 severity
    Hasan K. Aksoy, Ayşe Serap Karadağ, Uwe Wollina · 2020 · Dermatologic Therapy
71. COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation
    Marina Gennad'evna Bubnova, Aronov Dm · 2020 · PULMONOLOGIYA
72. Biases in Evaluating the Safety and Effectiveness of Drugs for the Treatment of COVID-19: Designing Real-World Evidence Studies
    Christel Renoux, Laurent Azoulay, Samy Suissa · 2021 · American Journal of Epidemiology
73. Machine Learning Approaches to Identify Patient Comorbidities and Symptoms That Increased Risk of Mortality in COVID-19
    Sakifa Aktar, Ashis Talukder, Md. Martuza Ahamad, A. H. M. Kamal, Jahidur Rahman Khan, Md. Protikuzzaman, Nasif Hossain, AKM Azad, Julian M.W. Quinn, Mathew A. Summers et al. · 2021 · Diagnostics
74. Sustainable spectrophotometric determination of antihypertensive medicines reducing COVID-19 risk via paired wavelength data processing technique - Assessment of purity, greenness and whiteness
    Sara El-Hanboushy, Hoda M. Marzouk, Yasmin Mohammed Fayez, Mohamed Abdelkawy, Hayam Mahmoud LOTFY · 2022 · Sustainable Chemistry and Pharmacy
75. The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials
    Eugenie Ruth Lumbers, Sarah J. Delforce, Kirsty G. Pringle, Gary R. Smith · 2020 · Frontiers in Medicine
76. Renin–Angiotensin–Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study
    Sascha Dublin, Rod L. Walker, James S. Floyd, Susan M. Shortreed, Sharon Fuller, Ladia H. Albertson-Junkans, Laura B. Harrington, Mikael Anne Greenwood-Hickman, Beverly B. Green, Bruce M. Psaty · 2020 · American Journal of Hypertension
77. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets
    Jimin Xu, Yu Xue, Richard Zhou, Pei‐Yong Shi, Hongmin Li, Jia Zhou · 2020 · Medicinal Research Reviews
78. Neutrophil-to-Lymphocyte Ratio Predicts Clinical Outcome of Severe Acute Exacerbation of COPD in Frequent Exacerbators
    Fangying Lu, Rong Chen, Ning Li, Xianwen Sun, Min Zhou, Qingyun Li, Yi Guo · 2021 · International Journal of COPD
79. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients
    Adriana J. J. Lammers, Richard M. Brohet, R.E.P. Theunissen, Corinna Köster, R. Rood, Dominique W. M. Verhagen, Kees Brinkman, R.J. Hassing, A. Dofferhoff, Rachida el Moussaoui et al. · 2020 · International Journal of Infectious Diseases
80. Heavy Disease Burden of High Systolic Blood Pressure During 1990-2019: Highlighting Regional, Sex, and Age Specific Strategies in Blood Pressure Control
    Mingming Chen, Xingyuan Zhang, Ye-Mao Liu, Ze Chen, Haomiao Li, Fang Lei, Juan‐Juan Qin, Yan‐Xiao Ji, Peng Zhang, Jingjing Cai et al. · 2021 · Frontiers in Cardiovascular Medicine
81. Risk factors for acute kidney injury in COVID-19 patients: an updated systematic review and meta-analysis
    Jialing Zhang, Qi Pang, Ting Zhou, Jiali Meng, Xingtong Dong, Zhe Wang, Aihua Zhang · 2023 · Renal Failure
82. Cardiovascular manifestation and treatment in COVID-19
    Yen-Bo Su, Ming‐Jen Kuo, Ting‐Yu Lin, Chian‐Shiu Chien, Yi-Ping Yang, Shih‐Jie Chou, Hsin‐Bang Leu · 2020 · Journal of the Chinese Medical Association
83. Thyroid cancer in the age of COVID-19
    Venessa Tsang, Matti L. Gild, Anthony Robert Glover, Roderick John Clifton-Bligh, Bruce G. Robinson · 2020 · Endocrine Related Cancer
84. Mega doses of retinol: A possible immunomodulation in Covid‐19 illness in resource‐limited settings
    Ish K. Midha, Nilesh Kumar, Amit Kumar, Taruna Madan · 2020 · Reviews in Medical Virology
85. Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
    Romil Singh, Sawai Singh Rathore, Hira Khan, Abhishek Bhurwal, Mack Sheraton, Prithwish Ghosh, Sohini Anand, Janaki Makadia, Fnu Ayesha, Kiran Sunil Mahapure et al. · 2022 · Frontiers in Medicine
86. A data-driven approach to identify risk profiles and protective drugs in COVID-19
    Pietro E. Cippà, Federica Cugnata, Paolo Ferrari, Chiara Brombin, Lorenzo Ruinelli, Giorgia Bianchi, Nicola Beria, Lukas Schulz, Enos Bernasconi, Paolo G. Merlani et al. · 2020 · Proceedings of the National Academy of Sciences
87. Mechanisms of Myocardial Injury in Coronavirus Disease 2019
    Aniket S. Rali, Sagar Ranka, Zubair I. Shah, Andrew J. Sauer · 2020 · Cardiac failure review
88. Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis
    Chang Chu, Shufei Zeng, Ahmed Abdallah Hasan, Carl‐Friedrich Hocher, Bernhard Karl Krämer, Berthold Hocher · 2020 · British Journal of Clinical Pharmacology
89. Potential benefits of dietary seaweeds as protection against COVID-19
    Kenichi Tamama · 2020 · Nutrition Reviews
90. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry
    Diego López‐Otero, Javier López‐País, Carla Eugenia Cacho Antonio, Pablo José Antúnez Muiños, Teba González-Ferrero, Marta Pérez-Poza, Óscar Otero García, Brais Díaz‐Fernández, María Bastos-Fernández, Noelia Bouzas‐Cruz et al. · 2020 · Revista Española de Cardiología (English Edition)
91. Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2
    Upinder Kaur, K. Kshitish Acharya, Ritwick Mondal, Amit Kumar Singh, Luciano Saso, Sasanka Chakrabarti, Sankha Shubhra Chakrabarti · 2020 · European Journal of Pharmacology
92. Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases
    Ravindra Kumar Sharma, Jing Li, Suraj Krishnan, Elaine M. Richards, Mohan K. Raizada, Rajesh Mohandas · 2021 · Clinical Science
93. Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study
    Mohammed Baqur S. Al‐Shuhaib, Hayder Obayes Hashim, Jafar M. B. Al‐Shuhaib · 2021 · Computers in Biology and Medicine
94. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy
    Harry F. Ridgway, Christos T. Chasapis, Konstantinos Kelaidonis, Irene Ligielli, Graham J. Moore, Laura Kate Gadanec, Anthony Zulli, Vasso Apostolopoulos, Thomas Mavromoustakos, John Matsoukas · 2022 · Viruses
95. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis
    Caldeira, Daniel, Alves, Mariana, Gouveia e Melo, Ryan, Silvério António, Pedro, Cunha, Nélson, Nunes-Ferreira, Afonso, Prada, Luisa, Costa, João, Pinto, Fausto J · 2020 · IJC Heart & Vasculature
96. COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients
    Bastien Genet, Jean‐Sébastien Vidal, Adrien Cohen, Clémence Boully, Maëlle Beunardeau, Louise Marine Harlé, Anna Gonçalves, Yasmina Boudali, Intza Hernandorena, Henri Bailly et al. · 2020 · Journal of the American Medical Directors Association
97. The COronavirus Pandemic Epidemiology (COPE) Consortium: A Call to Action
    Andrew Tan Chan, David A. Drew, Long H. Nguyen, Amit D. Joshi, Wenjie Ma, Chuan‐Guo Guo, Chun‐Han Lo, Raaj S. Mehta, Sohee Kwon, Daniel R. Sikavi et al. · 2020 · Cancer Epidemiology Biomarkers & Prevention
98. COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?
    Michael N. Doumas, Dimitrios Patoulias, Alexandra Katsimardou, Konstantinos Stavropoulos, Konstantinos P. Imprialos, Asterios I. Karagiannis · 2020 · Journal of Human Hypertension
99. COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients
    Jerzy Sieńko, Maciej Józef Kotowski, Anna Bogacz, Kacper Lechowicz, Sylwester Drożdżal, Jakub Rosik, Marek Sietnicki, Magdalena Sieńko, Katarzyna Kotfis · 2020 · Clinical Interventions in Aging
100. Blocking TNF signaling may save lives in COVID-19 infection
     Vitaly G. Ablamunits, Christopher S. Lepsy · 2022 · Molecular Biology Reports